
Dr. Reddy’s Laboratories launches innovative cancer drug Toripalimab in India
Dr. Reddy’s Laboratories has introduced Toripalimab (brand name Zytorvi) in India, marking the country’s third access to this innovative PD-1 inhibitor. The drug is approved for treating recurrent or metastatic nasopharyngeal carcinoma (NPC), offering a new treatment option that has shown a 48% reduction in disease progression or death risk. According to GLOBOCAN 2022 data,…